Earlier this month, Celltrion, Inc. (“Celltrion”) filed a copycat IPR petition directed against U.S. Patent No. 7,976,838 (“the ʼ838 patent”) that is essentially identical to a petition filed by Pfizer, Inc. (“Pfizer”). The PTAB recently instituted review of the ʼ838 patent based on Pfizer’s petition in IPR2017-01923. Celltrion’s copycat petition was accompanied by a motion
More Posts
FDA Approves Retacrit as a Biosimilar to Epogen®
District Court Grants Genentech’s Motions to Dismiss Celltrion’s Declaratory Judgment Actions in Herceptin® and Rituxan®-Related Suits
Sandoz Receives Complete Response Letter from FDA for Proposed Rituximab Biosimilar
Final Judgment Entered in Amgen v. Coherus Neulasta Litigation
Fujifilm and Mylan Announce Partnership to Commercialize Adalimumab Biosimilar
PTAB Institutes Review of AbbVie Patent Directed to Treatment of Chronic Plaque Psoriasis
PTAB Institutes Review of an AbbVie Patent Directed to Treatment of Psoriatic Arthritis Comprising Administration of Adalimumab
Celltrion and Teva File Declaratory Judgment Action Against Thirty-Seven Rituxan®-related Patents
Celltrion and Teva File Declaratory Judgment Action Against Thirty–Eight Herceptin®-related Patents
Subscribe: Subscribe via RSS
Blogs
Firm/Org